Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-07 EDT			5-day change	1st Jan Change
441.20 ^DKK	-2.24%		+0.36%	-29.32%

10:12am	Italy set to speed through $2.3 billion Novo Nordisk investment	RE
10:12am	Italy set to speed through $2.3 billion Novo Nordisk investment	RE

Novo Nordisk to Launch Late-stage Development of Amycretin Weight Management Treatment

Published on 2025-06-12 at 23:10

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Italy set to speed through $2.3 billion Novo Nordisk investment	10:12am	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	10:12am	RE
The importance of being constantly changing…	09:48am
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	08:30am	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	08:30am	RE
European shares fall as banks, mining stocks losses weigh	07-04	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	07-04	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	07-03	RE
NOVO NORDISK : UBS reiterates its Buy rating	07-03	ZD
Ascletis Pharma Begins Dosing Subjects in US Weight Management Drug Study; Shares Gain 3%	07-02	MT
How did Novo Nordisk lose the US market?	07-02
Novo Nordisk, WeightWatchers Expand Collaboration for Enhanced Access to Wegovy	07-01	MT
WW International, Inc. and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care	07-01	CI
How Novo Nordisk misread the US market for its weight loss sensation	07-01	RE
How Novo Nordisk misread the US market for its weight loss sensation	07-01	RE
Sector Update: Health Care Stocks Advance Tuesday Afternoon	07-01	MT
European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises to 2%	07-01	MT
Top Midday Stories: Powell Blames Tariffs for Rate Pause; Tesla Shares Fall on Trump-Musk Feud	07-01	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	07-01	MT
China's Innogen expects to complete weight-loss drug trials next year	07-01	RE
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	07-01	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	07-01	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	07-01	MT
NOVO NORDISK : Receives a Buy rating from UBS	07-01	ZD
Goldman Sachs Lowers Novo Nordisk Price Target to 745 Danish Kroner (from 775), Reiterates Buy - BN	07-01	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company